Cardiovascular Risk Reduction with Renin-Angiotensin Aldosterone System Blockade
2010
Cardiovascular Risk Reduction with RAS Blockade
Sample size: 9297
publication
Evidence: high
Author Information
Author(s): Nancy Houston Miller
Primary Institution: Stanford Cardiac Rehabilitation Program
Hypothesis
Inhibition of the renin-angiotensin aldosterone system (RAS) is an important target for cardioprotection.
Conclusion
Both angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) effectively control blood pressure and reduce target-organ damage.
Supporting Evidence
- ACEIs and ARBs lower the risk of cardiovascular events in high-risk patients.
- Patients with diabetes showed a significant reduction in cardiovascular events when treated with ramipril.
- Combination therapy with ACEIs and ARBs may provide additional benefits in certain populations.
Takeaway
This study shows that certain medications can help protect your heart and kidneys by controlling blood pressure.
Methodology
The study reviews existing data on the effectiveness of ARBs and ACEIs in managing hypertension and cardiovascular risk.
Participant Demographics
Patients with diabetes or evidence of cardiovascular disease.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI, 0.70 to 0.86
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website